Upcoming Allied Market Research
Acute Lung Injury Drug Market

Acute Lung Injury Drug Market

by Therapy (Medication, Devices), by Injury Type (Direct Injury, Indirect Injury) by End User (Hospitals & Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2022-2032

Report Code: A50574
Pages: NA
May 2023 | 25 Views
Author(s) : Onkar S
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

Acute lung injury (ALI) is a condition that can lead to respiratory failure and is associated with high mortality rates. ALI can be caused by a variety of factors, including infections, trauma, and exposure to toxins. The condition is typically characterized by inflammation and fluid accumulation in the lungs, which can impair gas exchange and lead to respiratory distress.
According to data from the Centers for Disease Control and Prevention (CDC), acute respiratory distress syndrome (ARDS), which is a severe form of ALI, affects approximately 200,000 people in the U.S. each year, with a mortality rate ranging from 34% to 46%. The incidence of ARDS is also increasing, with a reported increase of 50% between 1999 and 2013. A study published in the American Journal of Respiratory and Critical Care Medicine found that the incidence of ALI in the U.S. is 78.9 cases per 100,000 person-years. The study also reported that the mortality rate for ALI was 40.3%, with majority of deaths occurring within the first 48 hours of hospitalization.
In addition, lack of effective treatments is the difficulty in conducting clinical trials for ALI. Clinical trials for ALI require a large sample size and a prolonged period to monitor patient's condition. The condition can also progress rapidly, making it challenging to evaluate efficacy of medication accurately. Furthermore, the patient population for ALI is relatively small, which makes it difficult for pharmaceutical companies to invest in research and development for this condition. Despite these challenges, some promising approaches have shown potential in treating ALI. One approach is using mesenchymal stem cells (MSCs) to modulate the immune response and promote tissue repair. MSCs have immunomodulatory properties and can suppress the overactive immune response that contributes to lung injury. Clinical trials have shown that MSCs can improve outcomes in patients with ALI by reducing inflammation, promoting tissue repair, and improving lung function.
Furthermore, increase in incidences of ALI in older adults has significant implications for healthcare systems worldwide. ALI is associated with high mortality rates, and older adults may have a reduced ability to recover from the disease, leading to prolonged hospitalization and increased healthcare costs. The need for effective treatments for ALI is further highlighted by the aging population. Currently, there is no single medication that can cure ALI, and the focus of treatment is primarily on providing supportive care. However, as the incidence and prevalence of the disease increase, there is a growth in need for new and innovative treatments that can improve outcomes for older adults with ALI.
One potential area of focus for development of new treatments is the use of anti-inflammatory drugs. Inflammation plays a significant role in the development of ALI, and older adults may have a heightened inflammatory response. Developing drugs that can target inflammation specifically in older adults may be a promising avenue for research. Another potential area of focus is the development of vaccines for respiratory illnesses, such as influenza and pneumonia. Vaccines can help prevent respiratory infections, which are a leading cause of ALI in older adults. Developing vaccines that are specifically targeted towards older adults may be an effective way to reduce the incidence of ALI in this population.
New product launches to flourish in the market
Lack of effective treatments for acute lung injury (ALI) has created a significant unmet need in the market, and there is a growing demand for new therapies that can improve outcomes for patients with the disease. In recent years, there have been several new product launches in the ALI drug market, aimed at addressing this need.
One such product is Esbriet (pirfenidone), which was approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). While Esbriet is not specifically indicated for the treatment of ALI, it has been shown to have anti-inflammatory and anti-fibrotic effects, which may make it a promising therapy for the disease. Another product that has shown promise in the treatment of ALI is Angiotensin-(1-7) (Ang-(1-7)), a peptide that acts on the renin-angiotensin system to promote vasodilation and reduce inflammation. Several studies have shown that Ang-(1-7) can reduce lung injury and improve outcomes in animal models of ALI, and clinical trials are underway to evaluate its safety and efficacy in humans.
The acute lung injury (ALI) market has been witnessing an increase in new product launches in recent years. Several pharmaceutical companies are investing in research and development of new therapies for ALI, with the aim of improving outcomes for patients and addressing the significant unmet need in the market.
Segment Overview: 
By Therapy: The acute lung injury drug market is divided into medications and devices. Pharmacotherapy includes various drugs such as anti-inflammatory drugs, antibiotics, bronchodilators, and others that are used to treat ALI. Fluid Management includes the administration of intravenous fluids to maintain fluid balance and prevent complications such as renal failure. Inhaled Nitric Oxide (iNO) is a vasodilator drug that is delivered through a ventilator to improve oxygenation and reduce pulmonary hypertension in patients with ALI. Also in devices category; Mechanical ventilation involves the use of a machine to support breathing in patients with ALI, and can include invasive or non-invasive ventilation depending on the severity of the disease. In adjunctive procedures devices include various devices such as bronchoscopes, endotracheal tubes, and chest tubes that are used to assist with mechanical ventilation and support patients with ALI.
By Injury Type: The acute lung injury drug market is divided into direct injury and indirect injury. It is not entirely accurate to divide the acute lung injury (ALI) drug market into direct and indirect injury categories. The classification of ALI based on direct or indirect injury relates to the underlying causes of the condition and not necessarily the drugs used to treat it. ALI can be caused by both direct and indirect injuries to the lungs. Direct injury refers to damage to the lung tissue itself, such as from pneumonia or inhalation of toxic substances. Indirect injury, on the other hand, occurs as a result of conditions that affect the body as a whole, such as sepsis or trauma.
By End User: The acute lung injury drug market is divided into hospitals & clinics and others. In general, patients with ALI are initially treated in hospital settings, often in intensive care units (ICUs) where they can receive specialized care, including mechanical ventilation, oxygen therapy, and other supportive measures. In some cases, patients may be transferred to other facilities for specialized care, such as a rehabilitation center for physical therapy or a long-term care facility for ongoing support.
By Region: The Asia Pacific (APAC) acute lung injury (ALI) market is indeed one of the fastest-growing markets globally. The region is expected to witness significant growth in the ALI market due to the increasing prevalence of lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, which can lead to ALI. In addition, there is a growing demand for better healthcare infrastructure, technological advancements, and rising healthcare expenditure in the region. This has led to an increase in the adoption of advanced medical devices and equipment, including those used in the treatment of ALI.
Furthermore, increase in incidences of respiratory diseases in the region is driving the demand for ALI drugs and treatments. This has led to the development of new drugs and treatment options, which are expected to drive market growth in the coming years. Several countries in the APAC region, such as China, India, Japan, and South Korea, are key markets for ALI drugs and treatments. The increasing population and high prevalence of lung diseases in these countries are driving demand for ALI treatments.
Competitive analysis and profiles of the major players in the acute lung injury market, such as Bayer AG
GlaxoSmithKline plc., Apeptico Forschung Und Entwicklung GmBH, General Electric Company, Koninklijke Philips N.V., Linde plc., Medtronic plc., Ony Biotech Inc., Pfizer Inc. and Teva Pharmaceutical Industries Limited. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the acute lung injury market.     

Acute Lung Injury Drug Market Report Highlights

Aspects Details
By Therapy
  • Medication
    • Pharmacotherapy
    • Fluid Management
    • Inhaled nitric oxide
  • Devices
    • Mechanical Ventilation
    • Adjunctive Procedures Devices
By Injury Type
  • Direct Injury
  • Indirect Injury
By End User
  • Hospitals & Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players Bayer AG, GlaxoSmithKline plc, Apeptico Forschung Und Entwicklung GmBH, General Electric Company, Koninklijke Philips N.V., Linde plc, Medtronic plc, Ony Biotech Inc, Pfizer Inc., Teva Pharmaceutical Industries Limited

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Acute Lung Injury Drug Market

Start reading.
This Report and over 19,981+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,600
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers